You are here

SBIR Phase I:Radioactive Gold Labeled Bio-Microspheres for Cancer Treatment

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 1013818
Agency Tracking Number: 1013818
Amount: $149,361.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: BC
Solicitation Number: NSF 09-609
Timeline
Solicitation Year: 2010
Award Year: 2010
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
4040 Hypoint North
ROLLA, MO 65401
United States
DUNS: 190717025
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 CW Kim
 PhD
 (573) 364-2338
 ckim@mo-sci.com
Business Contact
 CW Kim
Title: PhD
Phone: (573) 364-2338
Email: ckim@mo-sci.com
Research Institution
N/A
Abstract

This Small Business Innovation Research (SBIR) Phase I project is to develop a novel, radiation delivery device as a safe and effective microbrachytherapy for the treatment of cancer. The radioactive gold labeled bio-microspheres will offer several advantages over the currently available systems. The advantages include 1) a lower density to achieve better biodistribution, 2) a radioisotope that allows therapeutic treatment, 3) a radioisotope that has imaging capability and 4) flexibility in patient treatment times due to on-site activation/preparation. None of the products on the market today incorporates all these advantages. Our team making this technology successful includes MO-SCI Corporation, the University of Missouri Research Reactor (MURR) and Wake IsoDose Technologies.
The broader/commercial impacts of this research are that the viable new radiotherapy microsphere can be safely used to treat patients with malignant tumors (cancer), rheumatoid arthritis, and related diseases; and that the technology combines features that interventional radiologists and radiation oncologists have both wanted for years but no product yet offers. The radiogold labeled bio-microsphere technology offers both a diagnostic as well as a therapeutic radioisotope in one product, simplifying the overall treatment process by reducing the number of invasive therapies required to treat the patient as effectively as possible. All other therapies only offer one feature or the other.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government